

Substitute PTO/SB/8A (08-00)







Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/996,354	
			Filing Date	October 31, 2001	
			First Named Inventor	BROWN, Dennis M.	
			Group Art Unit	1623	
Examiner Name					
Attorney Docket Number	A-70614/RFT/THR (468899-8)				
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>[Signature]</i>	A1	5,786,344 A	07-1998	RATAIN et al.	
<i>[Signature]</i>	A2	5,916,913 A	06-1999	JOSEPH	
<i>[Signature]</i>	A3	6,013,626 A	01-2000	MOORE et al.	
<i>[Signature]</i>	A4	6,168,619 B1	01-2001	DINH et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	B1	EP 0 037 175 A1	10-1981	EFAMOL LTD		
	B2	WO 00/00238 A1	01-2000	QUANAM MEDICAL CORP		
	B3	WO 00/47197 A1	08-2000	QUANAM MEDICAL CORP		
	B4	WO 01/68098 A2	09-2001	CHEMGENEX		
	B5	WO 02/26220 A2	04-2002	UNIV NORTH CAROLINA		
	B6	GB 953 955 A	04-1964	CIBA LTD		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ⁶
AAO	C1	LIU JH, et al., "Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study." Urology. 2001 Apr;57(4):650-4.				
ATO	C2	FONG WF, et al., "Partial synergism between dextran-conjugated doxorubicin and cancer drugs on the killing of multidrug resistant KB-V1 cells." Anticancer Res. 1996 Nov-Dec;16(6B):3773-8. (Abstract) DATABASE BIOSIS Online. Biosciences Information Service, Philadelphia, PA 1996, Acc. No. PREV199799428437				
MO	C3	BELISARIO JC. "Topical cytotoxic therapy for cutaneous cancer and precancer." Arch Dermatol. 1965 Sep;92(3):293-302; discussion 302-3. (Abstract) DATABASE MEDLINE Online Acc. No. NLM11851254				
AAO	C4	GOMEZ GA et al., "Chemotherapy of the terminal phase of chronic myelocytic leukemia with combinations of colchicines derivatives and purine analogs." Leukemia Research (1978) (Abstract) retrieved from STN EMBASE Caesar Acc. No. 1186 DATABASE EMBASE Online, Elsevier Science Publishers, Amsterdam. Acc. NO. 79008257 Embase				
ATO	C5	MASHIMA Y, et al. "Combination chemotherapy in isolation perfusion: use of mitotic inhibitors in pretreatment of V x 2 carcinoma undergoing isolation perfusion with alkylating agents." Cancer Chemother Rep. 1972 Apr;56(2):175-81.				
MAN	C6	STOLINSKY DC, et al., "Rotational therapy with a colchicine analog in chronic granulocytic leukemia." Oncology. 1980;37(1):62-3.				
NO consider NO	C7	MARRÓN GASCA et al., "Colchicine-podophyllotoxin combination in the treatment of preepithelial squamoid and cutaneous epitheliomas." Actas Dermo-Sifilograficas=Spain=1974-Jul-Aug-65(7-8):388-394. NO translation				
	C8					

Examiner Signature	<i>[Signature]</i>	Date Considered	<i>[Signature]</i> 6/9/2003
--------------------	--------------------	-----------------	-----------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. 1105656_1.DOC